Bone Biologics (NASDAQ:BBLG) Releases Earnings Results, Beats Expectations By $0.11 EPS

Bone Biologics (NASDAQ:BBLG) announced its earnings results on Thursday. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.11, FiscalAI reports.

Bone Biologics Price Performance

Bone Biologics stock traded down $0.03 during mid-day trading on Thursday, reaching $1.27. The stock had a trading volume of 13,541 shares, compared to its average volume of 20,423. The company has a market capitalization of $2.28 million, a price-to-earnings ratio of -0.34 and a beta of 0.89. The company has a 50-day moving average price of $1.26 and a two-hundred day moving average price of $1.50. Bone Biologics has a one year low of $1.05 and a one year high of $6.75.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Bone Biologics currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC increased its position in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the period. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. 34.30% of the stock is owned by institutional investors.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.